All Pharma News
LEO Pharma Publishes Phase 3 Data On Chronic Hand Eczema

LEO Pharma Publishes Phase 3 Data On Chronic Hand Eczema
BUSINESSWIRE
18 Jul 2024
Share Share
FDA Approves Adbry Autoinjector fo Adults with Moderate-to-Severe (AD)

FDA Approves Adbry Autoinjector fo Adults with Moderate-to-Severe (AD)
BUSINESSWIRE
13 Jun 2024
Share Share
Leo’s single-dose autoinjector secures FDA approval for atopic dermatitis

Leo’s single-dose autoinjector secures FDA approval for atopic dermatitis
Justine Ra PHARMACEUTICAL TECHNOLOGY
13 Jun 2024
Share Share
Leo Pharma As Biologic Tralokinumab Receives Supp Approval in US

Leo Pharma As Biologic Tralokinumab Receives Supp Approval in US
FDA
12 Jun 2024
Share Share
LEO Pharma China Psoriasis Phase 3 Data For Enstilar

LEO Pharma China Psoriasis Phase 3 Data For Enstilar
BUSINESSWIRE
07 May 2024
Share Share
LEO Pharma Delivers 13% Growth On Dermatology Performance

LEO Pharma Delivers 13% Growth On Dermatology Performance
BUSINESSWIRE
03 May 2024
Share Share
In year 2 under new CEO, troubled Leo Pharma makes progress

In year 2 under new CEO, troubled Leo Pharma makes progress
Kevin Dunleavy FIERCE PHARMA
12 Mar 2024
Share Share
Timber Pharmaceuticals Presents Late-Breaking Preliminary Results of TMB-001

Timber Pharmaceuticals Presents Late-Breaking Preliminary Results of TMB-001
BUSINESSWIRE
10 Mar 2024
Share Share
LEO Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial

LEO Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial
BUSINESSWIRE
09 Mar 2024
Share Share
LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data

LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data
BUSINESSWIRE
08 Mar 2024
Share Share